Top-News

HIKMA PHARMS PLC S/ADR Aktie News

Aktie
WKN:  ISIN:  US4312881091 US-Symbol:  HKMPY
41,96 $
-0,7715 $
-1,81%
36,063 € 08.12.25
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Dividende
0,96 $
Dividendenrendite
2,27%
Index-Zuordnung
-

HIKMA PHARMS PLC S/ADR News

08.12.25 - PR Newswire
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US PR Newswire
02.07.25 - PR Newswire
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US PR Newswire
28.06.25 - PR Newswire
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines PR Newswire
27.05.25 - PR Newswire
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-​hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) ...
27.05.25 - PR Newswire
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-​hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) ...
17.04.25 - PR Newswire
Hikma acquires Novugen's FDA-approved ANDA for trametinib
Hikma acquires Novugen's FDA-​approved ANDA for trametinib PR Newswire
14.01.25 - PR Newswire
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg PR Newswire

Newssuche

Videos

newspaper
08.12.25 -2,30%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »